Core Viewpoint - The announcement by Four Seasons Pharmaceutical (00460) regarding the inclusion of its innovative drug Anjiewei® in the updated National Basic Medical Insurance Drug List (2025) is a significant development for the company and the industry, as it ensures continued market access and potential growth for the product [1] Group 1: Product Development and Approval - Anjiewei® (sodium anaprazole enteric-coated tablets) is the first and only domestically developed proton pump inhibitor in China, approved for market in June 2023 [1] - The drug is indicated for the treatment of duodenal ulcers and was first included in the National Basic Medical Insurance Drug List in December 2023 [1] Group 2: Market Impact - The successful renewal of Anjiewei® in the 2025 National Basic Medical Insurance Drug List will stabilize market sales and benefit a larger patient population [1] - This renewal is expected to enhance the drug's penetration rate in relevant indications, providing momentum for long-term growth [1]
四环医药(00460)：创新药安久卫®成功续约纳入2025年国家基本医保药品目录